(Q46571253)

23 December 2017

title

Pilot study of saquinavir and lopinavir/ritonavir twice daily in protease inhibitor-naive HIV-positive patients (English)

1 reference

23 December 2017

1 reference

1 reference

1 reference

1 reference

James Hellinger

1

1 reference

23 December 2017

Calvin Cohen

2

1 reference

23 December 2017

Anne Morris

3

1 reference

23 December 2017

Sandy Sheble-Hall

4

1 reference

23 December 2017

Danielle Gordon

5

1 reference

23 December 2017

Clarissa Foy

6

1 reference

23 December 2017

Lenore Jackson-Pope

7

1 reference

23 December 2017

Abby Shevitz

8

1 reference

23 December 2017

Erno van Schaic

9

1 reference

23 December 2017

publication date

1 March 2005

1 reference

23 December 2017

published in

HIV Clinical Trials

1 reference

23 December 2017

volume

6

1 reference

23 December 2017

issue

2

1 reference

23 December 2017

page(s)

107-117

1 reference

23 December 2017

The prevalence of antiretroviral drug resistance in the United States

cites work

1 reference

https://api.crossref.org/works/10.1310%2FYGKE-7K4V-UF5R-4F1G

Ritonavir and saquinavir combination therapy for the treatment of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FYGKE-7K4V-UF5R-4F1G

In vitro antiviral interaction of lopinavir with other protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FYGKE-7K4V-UF5R-4F1G

Phenotypic changes in drug susceptibility associated with failure of human immunodeficiency virus type 1 (HIV-1) triple combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FYGKE-7K4V-UF5R-4F1G

Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FYGKE-7K4V-UF5R-4F1G

Saquinavir: a review of its use in boosted regimens for treating HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FYGKE-7K4V-UF5R-4F1G

Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FYGKE-7K4V-UF5R-4F1G

Pharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FYGKE-7K4V-UF5R-4F1G

Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FYGKE-7K4V-UF5R-4F1G

An objective case definition of lipodystrophy in HIV-infected adults: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FYGKE-7K4V-UF5R-4F1G

A summary of implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FYGKE-7K4V-UF5R-4F1G

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FYGKE-7K4V-UF5R-4F1G

Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FYGKE-7K4V-UF5R-4F1G

Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FYGKE-7K4V-UF5R-4F1G

The metabolic effects of lopinavir/ritonavir in HIV-negative men

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FYGKE-7K4V-UF5R-4F1G

Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FYGKE-7K4V-UF5R-4F1G

The effect of protease inhibitors on weight and body composition in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FYGKE-7K4V-UF5R-4F1G

Elevated resting energy expenditure among HIV-seropositive persons receiving highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FYGKE-7K4V-UF5R-4F1G

Clinical evaluation and management of metabolic and morphologic abnormalities associated with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FYGKE-7K4V-UF5R-4F1G

Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FYGKE-7K4V-UF5R-4F1G

10.1310/YGKE-7K4V-UF5R-4F1G

21 January 2018

Identifiers

DOI

1 reference

23 December 2017

1 reference

23 December 2017